CN Mobile Logo

Search form


Prostate Cancer

Prostate Cancer

PARP inhibitors are an active, novel, and exciting class of anticancer agents. They have shown clear patient benefit in gBRCA, HR-deficient, and other ovarian cancers.

Slide Show: An array of new tools, perspectives, and guidelines to help navigate the grey areas have been reported in recent days.

The use of multi-parametric magnetic resonance imaging could help avoid a repeat prostate biopsy in some men, according to a new study.

The addition of custirsen to docetaxel and prednisone failed to improve overall survival among patients with metastatic castration-resistant prostate cancer in a phase III trial.

An uncommon but significantly burdensome sequela of therapy for prostate cancer is pubic bone osteomyelitis in association with a pubosymphyseal urinary fistula.

Men who receive testosterone replacement therapy had an increased rate of favorable-risk prostate cancer compared to those who did not use the therapy, and a decreased rate of aggressive prostate cancer.


Subscribe to Prostate Cancer on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.